Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.
Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, Coluccino L, Vitale M, Scalia G, Gentile L, De Lorenzo C, Guarracino MR, Castaldo G, D'Argenio V, Szomolay B, Cerullo V, Pastore L. Tripodi L, et al. Among authors: capasso c. iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20. iScience. 2023. PMID: 37720092 Free PMC article.
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma.
Chiaro J, Kasanen HHE, Whalley T, Capasso C, Grönholm M, Feola S, Peltonen K, Hamdan F, Hernberg M, Mäkelä S, Karhapää H, Brown PE, Martins B, Fusciello M, Ylösmäki EO, Greco D, Kreutzman AS, Mustjoki S, Szomolay B, Cerullo V. Chiaro J, et al. Among authors: capasso c. Cancer Immunol Res. 2021 Aug;9(8):981-993. doi: 10.1158/2326-6066.CIR-20-0814. Epub 2021 Jun 8. Cancer Immunol Res. 2021. PMID: 34103348 Free PMC article.
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.
Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V. Capasso C, et al. Oncoimmunology. 2015 Oct 29;5(4):e1105429. doi: 10.1080/2162402X.2015.1105429. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141389 Free PMC article.
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V. Ylösmäki E, et al. Among authors: capasso c. Mol Ther. 2018 Sep 5;26(9):2315-2325. doi: 10.1016/j.ymthe.2018.06.008. Epub 2018 Jun 19. Mol Ther. 2018. PMID: 30005865 Free PMC article.
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: capasso c. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
333 results